Why Real Product Users Beat Actors in Telehealth UGC

The real users vs actors telehealth UGC debate comes up constantly in creative strategy conversations, and the framing usually treats it as a production question. It is not. It is a compliance question and a trust question simultaneously, and those two dimensions are more consequential for telehealth than for almost any other advertising category. This guide breaks down why real users outperform actors in the majority of telehealth contexts, when the equation changes, and how to build a testing framework that answers the question with your own performance data.

The three categories of people who appear in telehealth UGC ads are distinct from each other in important ways: real patients with genuine treatment experience, paid UGC creators who produce content in the style of a patient experience, and actors performing a scripted patient role. Each carries different compliance implications, different creative performance characteristics, and different risk profiles. Treating them as interchangeable is a mistake.

Why Real Users Outperform Actors in Telehealth

Medical decisions require trust at a level that consumer product purchases do not. When someone is considering a GLP-1 consultation, an HRT evaluation, or a men's health program, they are making a decision that involves their body, their health history, and often their sense of identity. The bar for persuasion is correspondingly higher. Performed emotion — even very well-performed emotion — does not clear that bar the way genuine experience does.

Audiences have become genuinely skilled at detecting the difference between an actor playing a patient and someone who has actually been through the experience. The micro-signals are subtle: the specific vocabulary someone uses when they have actually navigated a healthcare system, the way they reference the consultation process with the particular awkwardness of someone who found it easier or harder than expected, the offhand details that no briefing document would think to include. These signals add up to something that registers as authentic even when the viewer cannot articulate why.

The inverse is also true. Actors tend to hit the emotional beats that a script calls for with too much precision. The pause before the "revelation" moment lands too cleanly. The vocabulary is slightly too polished, the hesitations too well-placed. Viewers who are attuned to this — and health-motivated viewers tend to be careful readers of content — register it as performed and downgrade their trust accordingly.

The FTC Disclosure That Changes the Calculation

There is a compliance factor that should inform creative strategy before any performance testing happens. Under FTC guidelines, when an actor portrays a patient in an advertisement — meaning they are playing a character rather than sharing their own experience — this must be disclosed. The required disclosure language includes phrases like "Dramatization," "Actor portrayal," or "Actor depicting patient experience."

That disclosure is not just a legal formality. It is a signal that appears in the ad itself, visible to every viewer, that says: no real patient was willing or able to testify to this experience on camera. That is a materially different ad from one that features a person who has actually used the product. The disclosure can reduce ad performance meaningfully because it removes the testimonial credibility that is the primary reason telehealth UGC works in the first place.

This FTC requirement does not apply to paid UGC creators who are actual program users — if a creator has genuinely used the service, their content is a real testimonial even if they are being compensated for producing it, provided the compensation is disclosed. The key distinction is between someone who is playing a character versus someone who is sharing their genuine experience while being paid to do so.

When Actors or Non-User Creators Are the Right Choice

There are specific situations where using an actor or non-user creator is the more appropriate choice, and understanding when those situations apply matters as much as understanding why real users are usually better.

The most common is patient population sensitivity. In ED treatment, some women's health categories, addiction treatment, and certain mental health programs, real users are often unwilling to appear in advertising — the subject matter is too private, the stigma concern is too significant, or the personal exposure is too high. In these categories, finding actual users who will appear on camera is genuinely difficult, and the alternative to using actors or creative formats that do not require a real face on camera is simply not advertising at all.

A second situation is the demonstration of the platform's clinical process — showing what a consultation interface looks like, how messaging works, what an intake form involves. This kind of content is inherently staged because you are showing a process, not a personal experience. Using actors here is appropriate and the dramatization disclosure is straightforwardly applicable.

Third: some health topics require a level of articulation and timing precision that most real users cannot produce in a self-filmed environment. For those contexts, a credentialed creator or health communicator who speaks from a professional perspective — not playing a patient, but contributing their expert viewpoint — is a legitimate alternative that does not require either a real patient or an actor in a patient role.

Recruiting Real Users for UGC

Building a pipeline of real users as UGC creators requires a proactive approach. Post-purchase and post-intake email campaigns that invite satisfied patients to apply as content creators are the most reliable channel. The messaging should be transparent: you are looking for patients who have had a positive experience and are comfortable sharing it on camera, in exchange for compensation.

Social media channels are a secondary sourcing path. Patients who are already publicly documenting their experience with a treatment program — posting about their GLP-1 journey on TikTok, sharing their HRT experience on Instagram — are self-identified candidates. A direct outreach to those individuals explaining that you are the brand they are already talking about and offering to compensate them for produced content is a natural conversion.

The challenge with real users is quality consistency. Someone who has a genuine experience does not automatically know how to translate it into engaging video content. Production support — basic guidance on framing, lighting, audio, and pacing — can close most of that gap without compromising authenticity. What you want to avoid is scripting so tightly that the specific language and personal details that make real-user content compelling get edited out.

Managing Consent and Privacy

HIPAA does not technically apply to marketing content — it applies to medical records and the handling of protected health information by covered entities. However, patients appearing in advertising should sign a clear, comprehensive model release that explains specifically how the content will be used, where it will be distributed, and for how long. A release signed for organic social use does not automatically cover paid advertising, paid amplification from the brand account, or whitelisting.

Be explicit in the release about paid advertising. Patients who are comfortable appearing in an organic post may not be comfortable when they see their face in a retargeting ad being shown to their family members or colleagues. Clarifying this upfront, before production, avoids situations where you need to pull content that has already been produced and is performing well.

The Testing Framework

The definitive way to answer the real users vs actors question for your specific audience is to run a structured A/B test. Take the same core message — the same hook, the same narrative arc, the same call to action — and produce it with a real user and with a paid creator who is not a genuine program user. Run both with identical targeting and identical spend. Measure cost per consultation as the primary metric, not click-through rate or video views.

This test will not always produce the same result across different telehealth categories. In GLP-1 and TRT, where real users are relatively accessible and willing to appear on camera, real users typically win. In ED and some women's health categories, the population dynamics make the test harder to run with true equivalence, but the principle still applies: test rather than assume.

Once you have performance benchmarks from the test, use them to guide your production budget allocation. If real user content performs at a significantly lower cost per consultation than creator content in your category, invest the sourcing effort required to build a real-user pipeline. If the gap is small, the operational simplicity of working with professional creators may justify the trade-off. The data should make that decision, not intuition.